Recent News

• 03.30.2026 - Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
• 03.13.2026 - Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
• 03.12.2026 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.09.2026 - Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
• 02.16.2026 - Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
• 11.18.2025 - Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
• 11.12.2025 - Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
• 11.10.2025 - Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Recent Filings

• 03.12.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.09.2026 - 8-K Current report
• 03.09.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.11.2026 - EFFECT Notice of Effectiveness
• 02.02.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 01.06.2026 - EFFECT Notice of Effectiveness
• 01.02.2026 - CORRESP Correspondence
• 12.30.2025 - S-3/A Registration statement under Securities Act of 1933